Taro Pharmaceutical Industries (NYSE:TARO) is scheduled to be issuing its quarterly earnings data after the market closes on Thursday, August 8th. Analysts expect the company to announce earnings of $1.96 per share for the quarter.
Taro Pharmaceutical Industries (NYSE:TARO) last announced its quarterly earnings data on Wednesday, May 22nd. The company reported $1.52 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $2.26 by ($0.74). Taro Pharmaceutical Industries had a net margin of 42.06% and a return on equity of 13.44%. The business had revenue of $179.92 million during the quarter, compared to analyst estimates of $189.90 million. On average, analysts expect Taro Pharmaceutical Industries to post $9 EPS for the current fiscal year and $10 EPS for the next fiscal year.
NYSE TARO traded down $0.42 during trading hours on Tuesday, hitting $79.11. The company’s stock had a trading volume of 1,854 shares, compared to its average volume of 41,009. The stock has a fifty day moving average of $83.77. Taro Pharmaceutical Industries has a twelve month low of $76.93 and a twelve month high of $116.49. The firm has a market cap of $3.09 billion, a price-to-earnings ratio of 11.06 and a beta of 0.48.
TARO has been the topic of several analyst reports. TheStreet lowered shares of Taro Pharmaceutical Industries from a “b-” rating to a “c” rating in a report on Thursday, May 23rd. ValuEngine lowered shares of Taro Pharmaceutical Industries from a “hold” rating to a “sell” rating in a report on Thursday, May 23rd. Finally, Zacks Investment Research lowered shares of Taro Pharmaceutical Industries from a “hold” rating to a “strong sell” rating in a report on Thursday, June 13th.
About Taro Pharmaceutical Industries
Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, engages in the development, manufacture, and marketing of pharmaceutical products in the United States, Canada, Israel, and internationally. It offers prescription and over-the-counter pharmaceutical products focusing on primary areas, including topical creams and ointments, liquids, capsules, and tablets in the dermatological and topical, cardiovascular, neuropsychiatric, and anti-inflammatory therapeutic categories.
Recommended Story: Insider Trading
Receive News & Ratings for Taro Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taro Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.